142 results about "Tumor imaging" patented technology

The invention discloses an AIE type fluorescent probe with tumor targeting as well as preparation and application thereof, and belongs to the technical field of medicines, the probe can accurately target HDAC6 high-expression tumor cells, the specific binding capacity of the probe reduces interference to normal cells, and the detection accuracy is improved. The probe is fused with AIE performance dye molecules and emits strong fluorescence during aggregation, so that the imaging sensitivity and definition are remarkably enhanced. By optimizing the structure and synthesis conditions, the fluorescence intensity and stability of the probe are improved, the sensitivity of early tumor detection is ensured, and the survival rate and life quality of patients are improved. The preparation method is simple, convenient, feasible, low in cost and beneficial to practical application. The probe can be used for preparing tumor detection products, assisting in tumor diagnosis and classification, monitoring treatment changes and evaluating the curative effect. High-precision imaging can be realized in the aspect of tumor imaging, the method can be used for evaluating curative effect and guiding formulation of subsequent treatment schemes, and the application prospect is wide.

The invention relates to a targeted drug delivery carrier based on mesoporous polydopamine nanoparticles and application thereof.The targeted drug delivery carrier is galactose modified mesoporous dopamine coordinated with manganese ions, lysine is adopted in the carrier synthesis step to provide an alkaline environment needed by dopamine polymerization, the polymerization process is simplified, and the drug delivery efficiency is improved. Meanwhile, lysine can be introduced into the mesoporous polydopamine; and the drug loading capacity of the carrier is improved. The carrier gathers multifunctionality of drug delivery, tumor imaging and treatment, provides a comprehensive new method for tumor treatment, and enhances individuation and precision of treatment.

The invention relates to a radionuclide-labeled glucose derivative molecular probe and application thereof, and belongs to the technical field of nuclear medicine. According to the present invention, propargyl glycine is used to synthesize an amino acid skeleton, and the amino acid skeleton reacts with glucose azide to prepare a series of radionuclide-labeled glucose derivative molecular probes, such as [68Ga] Ga-NOTA-SDG, [68Ga] Ga-NOTA-DDG, [68Ga] Ga-NOTA-TDG, [68Ga] Ga-DOTA-SDG, [68Ga] Ga-DOTA-DDG and the like; the glucose derivative molecular probe labeled by the series of radionuclides has the advantages of being simple and rapid in labeling, high in radiolabeling yield and good in stability, can accurately position tumors, has good tumor uptake and lower non-target tissue uptake, and has great application prospects in preparation of broad-spectrum tumor imaging agents.

The invention provides a target Her2 nuclide probe as well as a preparation method and application thereof, and relates to the technical field of nuclide probes. The target Her2 nuclide probe comprises a compound which is labeled by radionuclide and is shown in a formula I. The target Her2 nuclide probe can be used as a diagnosis and treatment reagent in human or animal Her2 protein high expression lesions, and is especially used as a tumor imaging agent and a radionuclide treatment drug. In animal experiments, the tumor / muscle ratio of the radioactive complex is high, and the radioactive complex has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.

The invention discloses a tumor heterogeneity analysis method and equipment based on super-resolution microscopic imaging, and relates to the field of medical image analysis. The method comprises the steps that a tumor imaging result is obtained, the tumor imaging result is generated through a super-resolution microscopic imaging technology, and the tumor imaging result comprises a tumor image; determining a target area of the tumor image; based on the tumor imaging result, quantitative analysis parameters are determined, and the quantitative analysis parameters are used for quantifying capillary features of at least two dimensions of tumor capillaries in the target area; on the basis of the quantitative analysis parameters, tumor heterogeneity analysis is conducted on different target areas, heterogeneity analysis results are obtained, and different target areas belong to the same tumor or different tumors. By adopting the scheme provided by the invention, the quantitative analysis parameters are generated based on the tumor imaging result, and quantitative analysis of tumor microvessel characteristics is realized, so that the accuracy of tumor heterogeneity analysis is improved.

The invention relates to the technical field of tumor fluorescence contrast agents, and particularly provides a conjugate of indocyanine green and multi-arm polyethylene glycol or pharmaceutically acceptable salt of the conjugate and a preparation method and application of the conjugate, the conjugate has the structural formula shown in the formula (I), the binding capacity of the conjugate and serum protein is remarkably reduced, and the conjugate can be applied to tumor fluorescence contrast agents. According to the present invention, the tumor targeting property is significantly improved, and the tumor is accumulated and detained in the tumor tissue, such that the targeted treatment or the high-resolution imaging is achieved so as to achieve the accurate tumor positioning and diagnosis, the high application value is provided, and the new method is developed for the tumor imaging and the treatment.

The invention relates to the technical field of nuclide probes, and discloses a targeted PARP nuclide probe and a preparation method and application thereof, and the targeted PARP nuclide probe comprises a radionuclide labeled compound as shown in formula I; the targeted PARP nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high PARP protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

The invention provides a benzene azepine derivative, a radioactive probe and application thereof, and belongs to the technical field of biological medicine. According to the present invention, the benzazepine derivative is modified, and the hydrophilic or lipophilic side chain is introduced, such that the prepared benzazepine derivative can be used as the V2R targeting precursor for application, the specific V2R targeting can be achieved, and the new molecular tool is provided for the subsequent V2R positive tumor diagnosis and treatment. The radioactive probe combined with the 68Ga marker shows a good tumor imaging effect, can realize PET imaging of V2R positive tumors, is helpful for improving the accuracy of tumor diagnosis, can also be used for evaluating the treatment effect, has a relatively high target / non-target ratio, can better display the distribution of whole body V2R receptors, and has a good application prospect. The invention has various applications in cancer diagnosis and treatment.

The invention relates to the technical field of image fusion, in particular to an image processing system based on tumor imageomics, which improves an existing medical image fusion algorithm based on multi-scale characteristic frequency domain decomposition filtering, and after a fusion layering with a better representation effect on graphic information and focus information after first fusion is determined, the fusion layering is carried out on the image information and the focus information; and according to the image feature expression of the fusion layer and the focus feature expression, adaptively determining the fusion weight of image fusion of different feature image layers, thereby performing adaptive image fusion based on the adaptive fusion weight. The problem that a medical image fusion algorithm based on multi-scale characteristic frequency domain decomposition filtering is poor in universality and flexibility is solved, and the universality and flexibility of the obtained final fusion image are better and more accurate.

The present invention discloses a type I semi-cyanine photosensitizer, a type I targeted photosensitizer, and a preparation method and application thereof. The semi-cyanine photosensitizer can rapidly generate a large amount of O2 under light and hypoxic conditions. ·‑ , thereby achieving the effect of photodynamic therapy, and having good biocompatibility and biodegradability, it is an effective type I photosensitizer. In addition, the above-mentioned type I photosensitizer is reacted with phosphorus oxychloride in the presence of water to prepare a type I photosensitizer with tumor targeting. It can specifically target alkaline phosphatase, a biomarker highly expressed in tumors. Under the action of alkaline phosphatase, the photosensitizer can be enriched in the tumor area, thereby achieving precise tumor imaging and photodynamic therapy, which can effectively reduce the side effects of the photosensitizer and improve the inhibitory effect of the photosensitizer on tumors.

The invention provides a multi-modal segmentation method and system for brain tumor imaging. The method comprises the following steps: acquiring brain magnetic resonance imaging of multiple modals; preprocessing brain magnetic resonance imaging of multiple modes to obtain a preprocessing result of each mode; performing key region identification on the preprocessing result of each mode to obtain a key region corresponding to each mode; performing feature extraction on the key area corresponding to each mode to obtain an extraction feature corresponding to each mode; performing feature fusion on the extracted features corresponding to each mode to obtain combined features; performing convolution and pooling processing on the combined features to obtain a first processing result, and performing convolution and mapping processing to obtain a second processing result; then carrying out multi-modal fusion to obtain a multi-modal fusion feature; carrying out attention weighting on the multi-modal fusion features to obtain weighted features; through weighted features, receptive field extraction is performed to obtain the position information of the brain tumor, so that the recognition accuracy of the brain tumor can be improved.

The present invention provides a glutathione-activated co-assembled nanoprobe and a preparation method and application thereof, belonging to the technical fields of chemical synthesis, biological analysis and detection, tumor imaging and treatment. In the present invention, amphiphilic small molecule probes 1-Zn-PPA and 1-NLG are constructed, and the probes 1-Zn-PPA and 1-NLG can be co-assembled in a solution to form co-assembled nanoprobes 1-NPs. The nanoprobes 1-NPs can accumulate at the tumor site under the tumor EPR effect and the targeting action of cRGD on the probe surface, and disassemble under the action of GSH present in the tumor reducing environment to release Gd-containing hydrophilic small molecule 2-Gd, light / sound-sensitive drug Zn-PPA-SH and immune adjuvant drug NLG919. The nanoprobes 1-NPs can realize combined sonodynamic therapy / photodynamic therapy / immunotherapy of living tumors. The nanoprobes 1-NPs have good applications in fluorescence imaging, magnetic resonance imaging, and the preparation of tumor treatment drugs and tumor-killing devices.

The invention discloses a gamma-glutamyl transpeptidase catalytic hydrolysis induced charge upset polymer, which contains a gamma-glutamyl transpeptidase response element part and a fluorescent probe corresponding fragment part, the invention also discloses a preparation method of the polymer for turning charge by catalytic hydrolysis of gamma-glutamyltranspeptidase and an application method of the polymer in the field of tumor imaging. According to the present invention, the gamma-glutamyltranspeptidase catalytic hydrolysis electric charge overturning polymer is adopted as the response type tumor imaging probe, such that the electric charge can be converted from the negative or neutral state to the positive state so as to achieve the rapid uptake of the positively charged polymer by the tumor cells so as to achieve the rapid spraying imaging, and the probe response after the uptake is adopted so as to achieve the rapid spraying imaging; the imaging effect of the probe on the tumor is greatly improved, and the probe has important significance in solid tumor imaging for assisting a doctor in surgical resection.

The invention relates to the technical field of biology, and particularly discloses a tumor imaging biomarker quantitative analysis system based on multi-mode MRI voxel space coupling and application. According to the application, the spatial coupling relationship between blood brain barrier destruction and perfusion in a tumor can be quantitatively reflected through the voxel overlap region proportion of T1CE and CBF signals, the 1p / 19q state can be efficiently predicted, and accurate prediction of IDH mutation and WHO grading (2-3 grade vs.4 grade) is realized in cooperation with clinical factors, so that the application has a wide application prospect. And an efficient and potential noninvasive imaging biomarker is provided for ADG preoperative molecular typing and grading prediction.

The invention discloses a PET (positron emission tomography) imaging agent, a precursor and a probe for targeting an EphA2 receptor as well as a preparation method and application of the PET imaging agent, the precursor and the probe, and a radioactive probe which is formed by labeling a chelating agent (such as DOTA and NOTA) and a radionuclide (such as 68Ga) by taking bicyclic peptide as a targeting group is specifically combined with the EphA2 receptor highly expressed on the surface of a tumor cell. According to the invention, a conformation limitation strategy is adopted for transforming the peptide probe targeting EphA2 for the first time, the bicyclic peptide radioactive probe with excellent targeting performance and in-vivo imaging effect is obtained, the tumor uptake value is high, and tumor and non-tumor imaging is clear; and successful imaging in a fibrosarcoma model. According to the EphA2 receptor-targeted PET imaging agent provided by the invention, the precursor, namely the probe, has the advantages of simplicity in preparation, good targeting property, excellent imaging effect and the like, can be used for PET imaging diagnosis, prognosis evaluation and targeted therapy guidance of EphA2 positive tumors, and has good clinical value.

This invention discloses an ERβ-targeted hydrogen peroxide-responsive near-infrared fluorescent probe, its preparation method, and its applications, belonging to the field of medical technology. The fluorescent probes of this invention are dicyanomethylene-4H-benzodihydropyran compounds P1 and P2 containing borate ester groups, with the following structural formula. These fluorescent probes use DCM-OH as a backbone, acting as both a fluorophore and an ERβ ligand. The borate ester group is the H2O2 responsive group. The introduction of the borate ester group disrupts the push-pull effect of the DCM-OH fluorophore, preventing fluorescence emission. However, in a high-concentration H2O2 environment, the borate ester group is specifically cleaved by H2O2, subsequently exhibiting strong initiation fluorescence and enabling tumor imaging in vitro and in vivo. This invention brings new opportunities for the diagnosis and research of prostate cancer.

The present invention discloses a polythiocarbamate, its preparation method, and application. The structural formula of the polythiocarbamate of the present invention is: wherein m is a natural number between 110 and 117, and n is a natural number between 6 and 17. The polythiocarbamate of the present invention has excellent biocompatibility and degradability. It can self-assemble in aqueous phase to form nanoparticles and be used as a transport vehicle for fluorescent probes and hydrophobic anticancer drugs. It can specifically amplify H2S signals at tumor sites and can be used for efficient and highly selective tumor imaging and treatment, possessing great potential for clinical application.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

The present application relates to the technical field of cancer detection, in particular to a kind of tumor imaging guided photodynamic therapy reagent.The reagent is named ADS254BE / H2TPP NPs, which is composed of hydrophobic conjugated polymer ADS254BE and tetraphenylporphyrin H2TPP doped polymer microspheres, and the surface of the polymer microspheres also has PSMA modification layer.The reagent is prepared by uniformly mixing ADS254BE, H2TPP and PSMA solution, ultrasonic treatment, room temperature standing, and then evaporating solvent in the solution.The photodynamic diagnosis and treatment reagent provided by the present application shows bright red emission centered at 650nm, relatively large stoke shift, higher singlet oxygen generation rate, and good light stability and biocompatibility.The present application provides a feasible strategy for constructing new optical diagnosis and treatment integrated reagent, and is expected to promote the development of imaging guided photodynamic therapy.

The invention discloses an enzyme-activated fluorescent molecular precursor as well as a preparation method and application thereof. The enzyme-activated fluorescent molecular precursor has a chemical structure as shown in a formula I which is described in the specification. The invention develops an enzyme-activated fluorescent molecular precursor which can be used for real-time imaging of tumors by targeting exogenous enzyme to the tumors and specifically activating a probe at the tumors; according to the invention, the exogenous enzyme is introduced as an activation trigger, and normal cells do not have the exogenous enzyme, so that the problem of co-expression of the endogenous enzyme in non-tumor tissues can be avoided, background fluorescence signals can be reduced to the greatest extent, and the imaging specificity and accuracy are remarkably improved.

This invention discloses a water-soluble melanin CEST contrast agent, its preparation method, and its application, relating to the field of magnetic resonance imaging contrast agent technology. This contrast agent, its preparation method, and its application aim to solve the technical problem that existing contrast agents containing paramagnetic metals can damage liver and kidney function. This water-soluble melanin CEST contrast agent comprises the following components by weight: 2-3 parts ammonia, 40 parts ethanol, 100 parts deionized water, and 0.5 parts reaction substrate. The chemical shift corresponding to this contrast agent preparation method is 4.0 ppm, exhibiting good adaptability to acidic environments and suitability for use in the tumor microenvironment. It is polymerized using dopamine hydrochloride or 3,4-dihydroxyphenylalanine, with inexpensive, simple, and readily available raw materials, simple synthesis, and easy large-scale preparation. It achieves tumor imaging without the need for paramagnetic metal ions, avoiding the damage to liver and kidney function caused by heavy metal ions.

An arylboron compound, its preparation method, applications, and pharmaceutical compositions are disclosed for tumor imaging. The compound of formula (I) exhibits high fluorescence quantum efficiency through intramolecular charge transfer. The compound of formula (I) synthesized in this invention can be linked to different antibodies via Q3 at certain concentrations, allowing for precise targeting of corresponding tumors based on the antibody. This type of boron drug formulation can be used in boron neutron capture therapy to kill tumor cells. It exhibits better killing effects; the compound of formula (I) targets tumor cells through antigen-antibody interaction. After the boron-10-containing drug accumulates at the tumor site, neutron radiation triggers a nuclear reaction releasing alpha particles and... 7 Lithium particles kill cells; the range of these two particles is approximately 10 μm. High-energy-density heavy ions disrupt the DNA double helix structure in tumor cells, causing irreparable cell death. Simultaneously, the 10 μm distance avoids damage to normal cells and tissues.

The invention belongs to the technical field of artificial intelligence assisted medical treatment, and particularly relates to a PET / CT tumor imaging examination result prediction system based on a large language model. The system comprises an input module used for inputting information of a patient; the prediction module is used for analyzing the information of the patient according to the large language model to obtain a prediction result that the patient is possibly positive in PET / CT tumor imaging examination; and the output module is used for outputting the prediction result. The method can assist a doctor in deciding whether a patient needs to be subjected to PET / CT examination or not, so that the PET / CT examination is more reasonable, and the positive rate of the PET / CT examination is effectively improved. Therefore, the method has a good application prospect.

The present disclosure provides a 18F-labeled biphenyl compound, its intermediate, preparation method, pharmaceutical composition and application. The biphenyl compound disclosed in the present disclosure has a significant inhibitory effect on PD-1 and / or PD-L1, can effectively alleviate or treat cancer and other related diseases, and can be used in PET tumor imaging technology.

The present invention provides a near-infrared fluorescent probe targeting CYP1B1 enzyme and its preparation and use. The near-infrared fluorescent probe has a structural formula as shown in formula (I): wherein X=O or X=NH, located at the 4' position or the 5' position; Y is a connecting chain, comprising multiple ethylene glycol fragments or multiple alkyl groups. The present invention also relates to the use of the aforementioned probe, wherein the probe targets the specifically expressed tumor marker CYP1B1 enzyme and images the tumor site by specifically binding to the CYP1B1 enzyme. The probe will promote the application of molecular imaging probes in tumor imaging and has good application prospects and clinical transformation value in early diagnosis of tumors.

The application discloses a FAPI derivative containing 4-cyano thiazolidine modification and application thereof, relates to the field of drug compounds for diagnosing tumors, and provides a FAPI derivative containing 4-cyano thiazolidine modification, a chemical structural formula of which is shown as formula I. The FAPI derivative has good stability, is simple to prepare, has high radiochemical purity and good biological performance, and can be further used for clinical PET / CT tumor imaging, effectively solving the problems of low tumor uptake rate, short retention time and inability to further delay imaging of F-labeled FAPI probes. 18 The FAPI derivative containing 4-cyano thiazolidine modification can solve the problems of low tumor uptake rate, short retention time and inability to further delay imaging of F-labeled FAPI probes, and make up for the defects of the prior art.

The present invention relates to the fields of radiopharmaceutical chemistry and clinical nuclear medicine technology, and specifically to a D-proline-modified folate derivative and its use. The radioactive preparation obtained by labeling the D-proline-modified folate derivative with a radionuclide can be prepared by kitting. It has high radiochemical purity and good stability. It exhibits significant uptake at the tumor site in tumor-bearing mice, is significantly inhibited by inhibitors, has a good target / non-target ratio, and exhibits low renal uptake. It can be used as a novel tumor imaging agent targeting folate receptors.

We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.

The present application relates to the field of biological medicine, and provide a kind of targeting PSMA dimer compound and its derivative and application, the structure general formula of the dimer compound is as shown in formula (I).The dimer compound and its derivative of the present application have very high affinity and targeting to PSMA, after being labeled with suitable radionuclide, can be used as nuclear medicine molecular probe, to realize early diagnosis, staging and treatment of prostate cancer, 68 Ga]diPSMA-1-DOTA showed good tumor uptake in PET imaging of tumor mice.Therefore, this kind of radioactive complex has good clinical application prospect in tumor imaging targeting PSMA (especially PET imaging), and lays an important foundation for the radiotherapy application of [ 177 Lu]diPSMA-1-DOTA and [ 225 Ac]diPSMA-1-DOTA.

The application belongs to the field of fluorescent probes, and particularly relates to a tumor-targeting photothermal reagent based on fluoro-rhodamine, and a preparation method and application thereof. To solve the problems that most of existing photothermal reagents have difficulty in post-modification due to complex synthesis, poor biological compatibility due to large molecular weight, and lack of tumor targeting of these molecules, and generally need to be made into nanoparticles to enrich to the tumor site by EPR effect, the application develops a tumor-targeting photothermal reagent Tag-880-NHS based on fluoro-rhodamine, which has the characteristics of simple synthesis, good water solubility, good light stability, high photothermal conversion efficiency, and an absorption wavelength located in the NIR region, and can be used for labeling a specific targeting epidermal growth factor monoclonal antibody-panitumumab, and can be used in the fields of tumor imaging and treatment, and has important application value.